3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
Gemcitabine
56
pembrolizumab
50
Cisplatin
43
Magnetic Resonance Spectroscopy
27
enfortumab vedotin
22
Specimen Handling
22
Nivolumab
22
Cystectomy
18
durvalumab
16
Carboplatin
16
avelumab
15
Mitomycin
14
atezolizumab
13
Docetaxel
13
Cystoscopy
12
Fluorouracil
11
Radiation
9
Transurethral Resection of Bladder
8
Radiotherapy
8
Ipilimumab
8
sacituzumab govitecan
7
Standard of Care
7
Radiosurgery
7
Paclitaxel
7
Immunoglobulin G
7
Disulfides
7
erdafitinib
6
cemiplimab
6
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
lenvatinib
×
1 year
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled